Nanobiotix SA ADR NBTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $37.53
- Day Range
- $36.12–38.38
- 52-Week Range
- $4.93–57.14
- Bid/Ask
- $18.91 / $45.00
- Shares Outstanding
- 50.79M
- Market Cap
- $1.92B
- Volume/Avg
- 218,728 / 89,070
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 53.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 97
- Website
- https://www.nanobiotix.com
Valuation
|
Metric
|
NBTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 53.21 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NBTX
|
|---|---|
Quick Ratio | 1.05 |
Current Ratio | 1.09 |
Interest Coverage | −1.40 |
Quick Ratio
NBTX
Profitability
|
Metric
|
NBTX
|
|---|---|
Return on Assets (Normalized) | −35.44% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NBTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#ZT?n#$ | LOCK|%$LV | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|NY>#SS | LOCK|x>KX< | $71B | |||
| argenx SE ADR
ARGX
| LOCK|MSJcQ@ | LOCK|n^D | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|R#rm&z | LOCK|yrj | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fCfm?Mr | LOCK|cqb? | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&^$>!?sw | LOCK|zTTl$ | $26B | |||
| Moderna Inc
MRNA
| LOCK|%NY@^k | LOCK|MZk | $25B | |||
| Incyte Corp
INCY
| LOCK|W?W@$VH | LOCK|kM< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|BGP^wnw | LOCK|!@n | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&DRW@PH | LOCK|## | $16B |
United States